Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression

Oncology Reports

Volumn 9, Issue 2, 2002, Pages 307-312

  Liang, Ji An ^a   Shiau, Yu Chien ^b   Yang, Shih Neng ^a   Lin, Fang Jen ^a   Lin, Cheng Chieh ^a   Kao, Albert ^a   Lee, Cheng Chun ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy response; Malignant lymphoma; Multidrug resistance related protein; P glycoprotein; Technetium 99m tetrofosmin

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DIAGNOSTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; ORGANOPHOSPHORUS COMPOUND; PREDNISONE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE; VINCRISTINE;

ADULT; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036518698     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.2.307     Document Type: Article

References (24)

1. Wilson WH and Chabner BA: Principles of chemotherapy for lymphomas. In: The Lymphomas. Canellos GP, Lister TA and Sklar JL (eds.) W.B. Saunders, Philadelphia, pp235-245, 1998.
2. Neal AJ and Hoskin PJ: Lymphoma. In: Clinical Oncology: Basic Principle and Practice. Neal AJ and Hoskin PJ (eds.) Arnold, London, ppl62-174, 1997.
3. Barr L, Cowan R and Nicolson M: Heamatological malignancies. In: Oncology. Barr L, Cowan R and Nicolson M (eds.) Churchill Livingstone, New York, ppl50-155, 1997.
4. Yamaguchi M, Kita K, Miwa H, et al: Frequent expression of P-glycoprotein/MDR 1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995.
5. Niehans GA, Jaszca W, Brunetto V, et al: Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell immunoblastic lymphomas. Cancer Res 52: 3768-3775, 1992.
6. Webb M, Brun M, McNiven M, Couteur DL and Craft P: MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Hemematol 102: 710-717, 1998. (Pubitemid 28387053)
7. Zhan Z, Sandor VA, Gamelin E, et al: Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 89: 3795-3800, 1997. (Pubitemid 27227104)
8. Ballinger JR, Bannerman J, Boxen I, et al: Accumulation of Tc-99m tetrofosmin in breast tumour cells in vitro: role of multidrug-resistance P-glycoprotein. J Nucl Med 36 (Suppl. 5): 202, 1995.
9. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG and Moore MJ: Technetium-99-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 37: 1578-1582, 1996. (Pubitemid 26321652)
10. Nakamura K, Fujii H, Kubo A, Takami H, Satake S and Sugawara I: In vitro assessment of MDR-reversing agents by Tc-99m-MIBI or Tc-99m-Tetrofosmin. J Nucl Med 38 (Suppl. 5): 180, 1997.
11. Wolf H, Frieling B, Brenner W and Henze E: Uptake of Tc-99m-Sestamibi, Tc-99m-tetrofosmin and Tc-99m-furifosmin in sensitive and multidrug-resistant carcinoma cells. J Nucl Med 38 (Suppl. 5): 241, 1997.
12. Fukumoto M, Yoshida D, Akagi N, Kurohara A, Murata Y and Yoshida S: In vitro prediction of MDR and MRP: comparison of Tc-99m MIBI and Tc-99m tetrofosmin. J Nucl Med 39 (Suppl. 5): 216P, 1998.
13. Aigner RM, Fueger GF, Zinke W and Sill H: Tc-99m-tetrofosmin scintigraphy in Hodgkin's disease. Nucl Med Commun 18: 252-257, 1997.
14. Kao CH, Ho YJ, Shen YY and Lee JK: Evaluation of chemotherapy response in patients with small cell lung cancer using technetium-99m-tetrofosmin. Anticancer Res 19B: 2311-2315, 1999. (Pubitemid 29392541)
15. Fukumoto M, Yoshida D, Hayase N, Kurohara A, Akagi N and Yoshida S: Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study. Cancer 86: 1470-1479, 1999. (Pubitemid 29489780)
16. Kao CH, Tsai SC, Wang JJ, Ho YJ, Ho ST and Chang Lai SP: Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factor. Br J Haematol 113: 369-374, 2001. (Pubitemid 32523140)
17. Jaffe ES: Histopathology of the non-Hodgkin's lymphomas and Hodgkin's disease. In: The Lymphomas. Canellos GP, Lister TA and Sklar JL (eds.) W.B. Saunders, Philadelphia, pp77-106, 1998.
18. Marie JP: P-glycoprotein in adult hematologic malignancies. Hematol Oncol Clin North Am 9: 239-249, 1995.
19. Kostakoglu L, Guc D, Canpinar H, et al: P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 39: 1191-1197, 1998. (Pubitemid 28326149)
20. Piwnica-Worms D and Holman BL: Non-cardiac application of hexakis (alkyl-isonitrile) technetium-99m complexes. J Nucl Med 31: 1166-1167, 1990.
21. Higley B, Smith FW, Smith T, et al: Technetium-99m-l,2- bis(bis(2-ethoxyethyl)phosphino) ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 34: 30-38, 1993. (Pubitemid 23014224)
22. Kelly JD, Forster AM, Higley B, et al: Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 34: 222-227, 1993. (Pubitemid 23056400)
23. Hendrikse NH, Franssen EJ, van-der-Graaf WT, Vaalburg W and De Vries EG: Visualization of multidrug resistance in vivo. Eur J Nucl Med 26: 283-293, 1999. (Pubitemid 29139861)
24. Sun SS, Hsieh JF, Tsai SC, Ho YJ and Kao CH: Technetium-99m tetrofosmin mammoscintigraphic findings related to the expression of P-glycoprotein mediated multidrug resistance. Anticancer Res 20: 1467-1470, 2000. (Pubitemid 30628152)